- Conditions
- Venous Thromboembolism
- Interventions
- Semuloparin sodium, Enoxaparin sodium, Placebo
- Drug
- Lead sponsor
- Sanofi
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 2,326 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2009
- U.S. locations
- 1
- States / cities
- Bridgewater, New Jersey
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1–24
of 48
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Cytoreductive Surgery
- Interventions
- Serum procalcitonin lab draws
- Other
- Lead sponsor
- Eastern Regional Medical Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 20 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2016
- U.S. locations
- 1
- States / cities
- Philadelphia, Pennsylvania
- Conditions
- Heparin-induced Thrombocytopenia
- Interventions
- Blood Draw
- Procedure
- Lead sponsor
- University of Arizona
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 125 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2026
- U.S. locations
- 1
- States / cities
- Tucson, Arizona
- Conditions
- Stage I Multiple Myeloma, Stage II Multiple Myeloma, Stage III Multiple Myeloma
- Interventions
- bortezomib, lenalidomide, dexamethasone
- Drug
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years and older
- Enrollment
- 48 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2014
- U.S. locations
- 275
- States / cities
- Scottsdale, Arizona • Fairfield, California • San Diego, California + 184 more
- Conditions
- Blood Loss, Surgical, Coagulation Disorder
- Interventions
- Reltodecacog alfa, Usual Pharmacological Care
- Drug
- Lead sponsor
- VarmX B.V.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 800 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2031
- U.S. locations
- 19
- States / cities
- Chandler, Arizona • Phoenix, Arizona • Stanford, California + 14 more
- Conditions
- Community-acquired Pneumonia, Influenza, COVID-19
- Interventions
- Ceftriaxone, Moxifloxacin or Levofloxacin, Piperacillin-tazobactam, Ceftaroline, Amoxicillin-clavulanate, Standard course macrolide, Extended course macrolide, No systemic corticosteroid, Fixed-duration Hydrocortisone, Shock-dependent hydrocortisone, Fixed-duration higher dose Hydrocortisone, No antiviral agent for influenza, Five-days oseltamivir, Ten-days oseltamivir, No antiviral agent for COVID-19, Lopinavir / Ritonavir, Hydroxychloroquine, Hydroxychloroquine + lopinavir/ritonavir, Ivermectin, No immune modulation for COVID-19, Interferon beta-1a, Anakinra, Tocilizumab, Sarilumab, Local standard venous thromboprophylaxis, Therapeutic dose anticoagulation, Conventional low dose thromboprophylaxis, Intermediate dose thromboprophylaxis, Continuation of therapeutic dose anticoagulation, No immunoglobulin, Convalescent plasma, Delayed administration of convalescent plasma, No vitamin C, Vitamin C, No antiplatelet, Aspirin, P2Y12 inhibitor, No simvastatin, Simvastatin, Eritoran, Apremilast, Clinician-preferred mechanical ventilation strategy, Protocolised mechanical ventilation strategy, No renin-angiotensin system inhibitor, Angiotensin converting enzyme inhibitor, Angiotensin Receptor Blockers, ARB + DMX-200, No cysteamine, Cysteamine, Fixed-duration dexamethasone, Baloxavir Marboxil, Five-days oseltamivir + baloxavir marboxil, Ten-days oseltamivir + baloxavir marboxil, No endothelial modulator, Imatinib, No Immune Modulator for Influenza, Baricitinib, Nirmatrelvir/ritonavir, Remdesivir, Nirmatrelvir/ritonavir + remdesivir
- Drug · Other · Biological + 1 more
- Lead sponsor
- UMC Utrecht
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 20,000 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2028
- U.S. locations
- 11
- States / cities
- Jacksonville, Florida • Augusta, Georgia • Chicago, Illinois + 8 more
- Conditions
- Colon Cancer, Rectal Cancer
- Interventions
- Floxuridine, Oxaliplatin, CPT-11
- Drug
- Lead sponsor
- Memorial Sloan Kettering Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 52 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2000 – 2021
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- Unstable Angina, Myocardial Infarction, Acute Disease
- Interventions
- Angiomax (bivalirudin) anticoagulant
- Drug
- Lead sponsor
- The Medicines Company
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 13,800 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2003 – 2007
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- Atrial Fibrillation (AF), VTE
- Interventions
- PAUSE Perioperative DOAC Management, ASRA Perioperative DOAC Management
- Other
- Lead sponsor
- McMaster University
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 920 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2027
- U.S. locations
- 6
- States / cities
- Hartford, Connecticut • Evanston, Illinois • Boston, Massachusetts + 3 more
- Conditions
- Adverse Pregnancy Outcome
- Interventions
- Lovenox 40mg
- Drug
- Lead sponsor
- Endeavor Health
- Other
- Eligibility
- 18 Years to 60 Years
- Enrollment
- 20 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2027
- U.S. locations
- 1
- States / cities
- Evanston, Illinois
- Conditions
- Acute Respiratory Failure, Extracorporeal Membrane Oxygenation Complication, Bleeding
- Interventions
- HEP-IV
- Drug
- Lead sponsor
- University of Arizona
- Other
- Eligibility
- 18 Years and older
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2021
- U.S. locations
- 1
- States / cities
- Phoenix, Arizona
- Conditions
- Breast Cancer, Colorectal Cancer, Lung Cancer, Prostate Cancer, Veno-occlusive Disease
- Interventions
- dalteparin, standard therapy
- Drug
- Lead sponsor
- Alliance for Clinical Trials in Oncology
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 141 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 1998 – 2004
- U.S. locations
- 19
- States / cities
- Scottsdale, Arizona • Urbana, Illinois • Cedar Rapids, Iowa + 16 more
- Conditions
- Coronary Microvascular Disease, Ischemic Heart Disease, Myocardial Ischemia
- Interventions
- Bivalirudin, Adenosine, Heparin, Pressure-Temperature Sensor Guidewire, Guiding Catheter
- Drug · Device
- Lead sponsor
- NYU Langone Health
- Other
- Eligibility
- 18 Years to 125 Years
- Enrollment
- 206 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2026
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- Hemodialysis
- Interventions
- PTA alone without use of the GORE VIABAHN, GORE VIABAHN® Endoprosthesis with Heparin Bioactive Surface
- Other · Device
- Lead sponsor
- American Access Care
- Other
- Eligibility
- 18 Years to 70 Years
- Enrollment
- 140 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 2010
- U.S. locations
- 3
- States / cities
- Flushing, New York • The Bronx, New York • White Plains, New York
- Conditions
- Pancreatic Ductal Adenocarcinoma (PDAC)
- Interventions
- ONCObind (Onco-Seraph) 100 Filter
- Device
- Lead sponsor
- ExThera Medical Corporation
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 5 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024
- U.S. locations
- 1
- States / cities
- Oklahoma City, Oklahoma
- Conditions
- Cardiovascular Diseases, Thromboembolism
- Interventions
- Not listed
- Lead sponsor
- Mayo Clinic
- Other
- Eligibility
- Not listed
- Enrollment
- 385 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2001 – 2009
- U.S. locations
- 1
- States / cities
- Rochester, Minnesota
- Conditions
- Septic Shock
- Interventions
- Seraph-100 + State of the Art Care, State of the Art Care
- Device
- Lead sponsor
- ExThera Medical Corporation
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 15 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2027
- U.S. locations
- 9
- States / cities
- Washington D.C., District of Columbia • Brunswick, Georgia • Ann Arbor, Michigan + 5 more
- Conditions
- Oral Mucositis
- Interventions
- Palifermin, Heparin
- Drug
- Lead sponsor
- Swedish Orphan Biovitrum
- Industry
- Eligibility
- 18 Years to 45 Years
- Enrollment
- 44 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2010 – 2011
- U.S. locations
- 1
- States / cities
- Knoxville, Tennessee
- Conditions
- Acute Coronary Syndromes
- Interventions
- Switching from Fondaparinux to Bivalirudin or Unfractionated Heparin
- Drug
- Lead sponsor
- Medstar Health Research Institute
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 100 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2010
- U.S. locations
- 5
- States / cities
- Bridgeport, Connecticut • Washington D.C., District of Columbia • Miami, Florida + 2 more
- Conditions
- Small Cell Lung Cancer
- Interventions
- Etoposide, Cisplatin, enoxaparin sodium
- Drug
- Lead sponsor
- Massachusetts General Hospital
- Other
- Eligibility
- 18 Years and older
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 2008
- U.S. locations
- 4
- States / cities
- Boston, Massachusetts • Peabody, Massachusetts
- Conditions
- Other Fatty Acid Oxidation Disorders, Diabetes Mellitus, Insulin Resistance
- Interventions
- Lipid/heparin
- Other
- Lead sponsor
- Temple University
- Other
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 86 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2003 – 2015
- U.S. locations
- 1
- States / cities
- Philadelphia, Pennsylvania
- Conditions
- PreDiabetes
- Interventions
- Intralipid and heparin, Saline
- Other
- Lead sponsor
- Mayo Clinic
- Other
- Eligibility
- 25 Years to 65 Years
- Enrollment
- 60 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2024 – 2027
- U.S. locations
- 1
- States / cities
- Rochester, Minnesota
- Conditions
- Heparin-induced Thrombocytopenia
- Interventions
- Blood Draw
- Procedure
- Lead sponsor
- Vanderbilt University Medical Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 15 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2018
- U.S. locations
- 1
- States / cities
- Nashville, Tennessee
- Conditions
- Suspected Heparin-Induced Thrombocytopenia
- Interventions
- Desirudin or Argatroban®
- Drug
- Lead sponsor
- Canyon Pharmaceuticals, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 16 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2009
- U.S. locations
- 24
- States / cities
- Aurora, Colorado • Washington D.C., District of Columbia • Orlando, Florida + 20 more